Related Experiment Video

Updated: May 9, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Olaparib shows promise in multiple tumor types

    Cancer Discovery
    |July 13, 2013
    PubMed

    Insights

    The PARP inhibitor olaparib shows clinical benefit in patients with BRCA1/2 mutations for advanced breast and ovarian cancers. This phase II study also found effectiveness in pancreatic and prostate cancer patients.

    Area of Science:

    • Oncology
    • Genetics
    • Pharmacology

    Background:

    • Inherited BRCA1 and BRCA2 gene mutations are associated with increased risk for several cancers.
    • PARP inhibitors represent a targeted therapy approach for cancers with DNA repair deficiencies.

    Purpose of the Study:

    • To evaluate the efficacy of the PARP inhibitor olaparib in patients with inherited BRCA1/2 mutations across multiple cancer types.
    • To confirm previously observed clinical benefits and explore new indications for olaparib.

    Main Methods:

    • Phase II clinical study design.
    • Recruitment of cancer patients with confirmed BRCA1 and BRCA2 gene mutations.
    • Administration of olaparib and assessment of clinical outcomes.

    Main Results:

    • Confirmed clinical benefit of olaparib in advanced breast and ovarian cancers.
    • Demonstrated evidence of effectiveness for olaparib in pancreatic cancer.
    • Showcased effectiveness of olaparib in prostate cancer.

    Conclusions:

    • Olaparib demonstrates a consistent clinical benefit in BRCA1/2 mutated cancers, including breast, ovarian, pancreatic, and prostate cancers.
    • Olaparib is an effective targeted therapy option for a broader range of cancers with inherited BRCA mutations.

    More Related Videos

    Evaluating In Vitro DNA Damage Using Comet Assay10:43

    Evaluating In Vitro DNA Damage Using Comet Assay

    Published on: October 11, 2017

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    Tumor Progression02:07

    Tumor Progression

    Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
    Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
    Tumor Progression02:07

    Tumor Progression

    Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
    Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...